Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

201443 citationsJournal Articlebronze Open Access

Authors

E. Walter · Institute for Pharmaeconomic Research

Abstract

From a health economic perspective, CSAI is a cost-effective therapy and could be seen as an alternative treatment to LCIG or DBS for patients with advanced PD.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Botulinum Toxin and Related Neurological Disorders

Publication Details

Published in: Journal of Medical Economics

Volume 18, Issue 2, pp. 155-165

DOI: 10.3111/13696998.2014.979937

Field-Weighted Citation Impact: 2.27

Command Palette

Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

Authors

Abstract

Topics & Keywords

Publication Details